top of page

MEET OUR CBI TRAINEES

The University of Massachusetts Amherst Chemistry-Biology Interface (CBI) Program is dedicated to fostering a collaborative and innovative environment for aspiring scientists. Our program supports both resident and non-resident students with funding for their research.
 

CBI Funded Trainees are the cornerstone of our extensive alumni network. For more than 30 years, we've built a community of accomplished scientists, writers, and other professionals who got their start right here at UMass Amherst, as part of the CBI Program.

NIH Funded Trainee's

The CBI Program offers a couple funding opportunities, one of which is our NIH funded trainees. These trainees are granted an NIH Stipend which covers the majority of their funding for the year or 2 years that they are selected for funding. 

This funding is stipulated for Trainees in their second and/or third years of their PhD studies. 

Our NIH Trainee's also have access to travel funding support.

NIH Funded Traineeships are only available to US Citizens.

Laboratory Team Interaction
Lab Technician Working

UMass Funded Trainee's

The CBI Program offers a couple funding opportunities, one of which is our UMass funded trainees.
These trainees are granted an UMass Stipend which covers their Spring stipend for the year or 2 years that they are selected for funding.

This funding is stipulated for Trainees in their second and/or third years of their PhD studies.

Our UMass Trainee's also have access to travel funding support.

UMass Funded Traineeships are available to Non-Citizens as well as US Citizens.

Meet the CBI Trainees

Screenshot 2026-08-25 at 8.38_edited.jpg

NIH Trainee

Benjamin Adams

My focus is on developing improved CRISPR-based genome
imaging tools to study genome architecture dynamics in live cells.

  • LinkedIn
Headshot_edited.png

NIH Trainee

Kate Gregory

I study an ATP-binding cassette transporter in Mycobacterium smegmatis.

  • LinkedIn
Em Ambrosius_edited.jpg

NIH Trainee

Em Ambrosius

My work revolves around developing methods to speed up the study of enzymatic polymer degradation. These high-throughput methods will allow for a greater understanding of the fundamental process of polymer degradation and an increased ability to optimize this system for industrial use. 

  • LinkedIn
Screenshot 2026-08-25 at 8.48.04 AM.png

NIH Trainee

Kylie Paul

Research Summary Coming Soon

  • LinkedIn
Screenshot 2026-08-25 at 8.48.04 AM.png

NIH Trainee

Lauren Sweeney

Research Summary Coming Soon

  • LinkedIn
IMG_8167_edited.jpg

NIH Trainee

Donna Ter-Mkrtchyan

My research develops in vivo models to examine how disease-specific tau structures and local brain environments interact to drive selective tau aggregation and spread across specific brain regions and cell types in tauopathies, including Alzheimer’s disease.

  • LinkedIn
Rossetti_Headshot_edited.jpg

NIH Trainee

Isabella Rosetti

I use native mass spectrometry to study how intrinsically disordered protein Tau shifts its conformational ensemble during the early stages of aggregation.

  • LinkedIn
Kotfila Headshot_edited.jpg

NIH Trainee

Stephen Kotfila

My research focuses on the manipulation of vesicle trafficking in human macrophages by a mycobacterial outer membrane lipid, trehalose 6,6’-dimycolate (TDM).

  • LinkedIn
graceheadhsot_edited.jpg

NIH Trainee

Grace Jackson

Exploring the role of ornithine decarboxylation degradation by the ClpXP protease in
Caulobacter crescentus.

  • LinkedIn
CBI_Headshot_edited.jpg

NIH Trainee

Harun Cerkezi

I study how protein kinases and immune signaling pathways modulate changes in the integrity of the blood-brain barrier during cerebral malaria, with the goal of identifying therapeutic targets to improve cerebral malaria treatment.

  • LinkedIn
Patrick Murphy Headshot_edited.jpg

NIH Trainee

Patrick Murphy

Investigating the impact of peroxisomal dysfunction on lipid homeostasis in Arabidopsis thaliana 

  • LinkedIn
Image 2026-08-03 at 4.35_edited.jpg

UMass Trainee

Madhumita Pan

I work on developing biologics for cell membrane reprogramming via extracellular targeted protein degradation and exogenous protein delivery on the cell surface.

  • LinkedIn
Headshot pic_edited.jpg

UMass Trainee

Bakthavachalam Kannadasan

Developing microfluidic based fixed-target devices for addressing the sample delivery
challenges while performing time-resolved serial crystallography experiments.

  • LinkedIn
24122_248_edited.jpg

UMass Trainee

Mohamed Elanany

I develop biological and chemical degraders to selectively eliminate cryptochrome proteins post-translationally, enabling functional deconvolution of their role in circadian rhythm regulation independent of genetic knockout approaches.

  • LinkedIn
IMG_3210_edited.jpg

UMass Trainee

Yuanhang (Caroline) Luo

My research focuses on identifying and characterizing efflux pumps responsible for drug resistance in mycobacteria.

  • LinkedIn
IMG_9266_edited.jpg

UMass Trainee

Ngoc Le

Mechanical forces govern a vast majority of cellular activities, from migration, adhesion, differentiation, and proliferation to cancer progression. Mechanobiology seeks to elucidate not only how cells interact with one another and with their surrounding environment, but also how mechanical cues are transduced into biochemical signaling and downstream functional responses. My current project focuses on using DNA-based constructs to enable a robust, comprehensive, multiplexed, and high-throughput strategy for capturing transient mechanical forces and uncovering their dynamic regulation in living systems.

  • LinkedIn
PXL_20260506_224535119~2_edited.jpg

UMass Trainee

Harini Chandrababu

My research focuses on developing smart, pH-responsive nanomaterials that selectively kill bacterial biofilms without harming healthy human cells.

  • LinkedIn
Screenshot 2026-08-25 at 8.48.04 AM.png

NIH Trainee

Kelley Melanson

Research Summary Coming Soon

  • LinkedIn
1_Headshot_YimengSun_edited.png

UMass Trainee

Yimeng Sun

My research aims to harness synthetic ribonucleoprotein complexes, which comprise engineered RNAs
and RNA-binding effector proteins, to achieve targeted protein degradation in mammalian cells, thereby
broadening therapeutic opportunities for diseases driven by pathogenic proteins.

  • LinkedIn
bottom of page